XML 74 R53.htm IDEA: XBRL DOCUMENT v3.25.1
ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Schedule of Consideration for Mirati Acquisition (Details) - Mirati Therapeutics - USD ($)
$ in Millions
3 Months Ended
Jan. 23, 2024
Mar. 31, 2024
Business Acquisition [Line Items]    
Total consideration $ 4,801  
Plus: Fair value of CVRs 248  
Total consideration allocated 4,935  
Common Stock    
Business Acquisition [Line Items]    
Total consideration 4,596  
Equity    
Business Acquisition [Line Items]    
Total consideration 205  
Unvested Equity Awards    
Business Acquisition [Line Items]    
Payments To Acquire Businesses, Unvested Stock Awards $ (114)  
Unvested Equity Awards | Selling, general and administrative    
Business Acquisition [Line Items]    
Total consideration   $ 60
Unvested Equity Awards | Research and development    
Business Acquisition [Line Items]    
Total consideration   $ 54